1
|
Goulard M, Dosquet C, Chomienne C. [Towards a personalized pretransplantation conditioning in patients with myelodysplastic syndromes]. Med Sci (Paris) 2018; 34:9-11. [PMID: 29384085 DOI: 10.1051/medsci/20183401002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Marie Goulard
- Inserm UMR-S-1131, 1, avenue Claude Vellefaux, 75010 Paris, France
| | - Christine Dosquet
- Inserm UMR-S-1131, 1, avenue Claude Vellefaux, 75010 Paris, France - APHP, Hôpital Saint-Louis, unité de biologie cellulaire, 1, avenue Claude Vellefaux, 75010 Paris, France
| | - Christine Chomienne
- Inserm UMR-S-1131, 1, avenue Claude Vellefaux, 75010 Paris, France - APHP, Hôpital Saint-Louis, unité de biologie cellulaire, 1, avenue Claude Vellefaux, 75010 Paris, France
| |
Collapse
|
2
|
Mosca M, Vertenoeil G, Toppaldoddi KR, Plo I, Vainchenker W. [Not Available]. Bull Cancer 2016; 103:S16-28. [PMID: 27494969 DOI: 10.1016/s0007-4551(16)30142-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
BIOLOGICAL ASPECTS OF JAK/STAT SIGNALING IN BCR-ABL-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS: Myeloproliferative disorders more recently named Myeloproliferative neoplasms (MPN) display several clinical entities: chronic myeloid leukemia (CML), the classical MPN including polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF) and atypical and unclassifiable NMP. The term MPN is mostly used for classical BCR-ABL-negative (myeloproliferative disorder) (ET, PV, PMF). These are clonal diseases resulting from the transformation of an hematopoietic stem cell and leading to an abnormal production of myeloid cells. The genetic defects responsible for the myeloproliferative abnormalities are called « driver » mutations and all result in deregulation of the cytokine receptor / JAK2 / STAT axis. Among them, JAK2, the thrombopoietin receptor (MPL) and calreticulin (CALR) mutations are found in around 90% of the cases. These driver MPN mutations can be associated with other driver mutations also found in other hematological malignancies, especially in PMFs. These are chronic diseases with major risks being thrombosis, hemorrhage and cytopenias for PMF and the long-term progression to myelofibrosis and the transformation to leukemia. Most recent therapeutic have focused on targeting the JAK2 signaling pathway directly by inhibitors of JAK2 or indirectly. Interferon a allows in some cases hematologic and molecular remission patients.
Collapse
Affiliation(s)
- Matthieu Mosca
- Inserm UMR 1170, Gustave Roussy, Villejuif, 94805, France; Université Paris-Saclay, UMR 1170, Gustave Roussy, Villejuif, 94805, France; Gustave Roussy, UMR 1170, Villejuif, 94805, France
| | - Gaëlle Vertenoeil
- Signal Transduction & Molecular Hematology Unit, Ludwig Institute for Cancer Research, Brussels B-1200, Belgium; De Duve Institute, Université catholique de Louvain, Brussels B-1200, Belgium
| | - Katte Rao Toppaldoddi
- Inserm UMR 1170, Gustave Roussy, Villejuif, 94805, France; Université Paris-Saclay, UMR 1170, Gustave Roussy, Villejuif, 94805, France; Gustave Roussy, UMR 1170, Villejuif, 94805, France
| | - Isabelle Plo
- Inserm UMR 1170, Gustave Roussy, Villejuif, 94805, France; Université Paris-Saclay, UMR 1170, Gustave Roussy, Villejuif, 94805, France; Gustave Roussy, UMR 1170, Villejuif, 94805, France
| | - William Vainchenker
- Inserm UMR 1170, Gustave Roussy, Villejuif, 94805, France; Université Paris-Saclay, UMR 1170, Gustave Roussy, Villejuif, 94805, France; Gustave Roussy, UMR 1170, Villejuif, 94805, France.
| |
Collapse
|
3
|
Couronné L, Bastard C, Gaulard P, Hermine O, Bernard O. [Molecular pathogenesis of peripheral T-cell lymphoma (1): angioimmunoblastic T-cell lymphoma, peripheral T-cell lymphoma, not otherwise specified and anaplastic large cell lymphoma]. Med Sci (Paris) 2015; 31:841-52. [PMID: 26481023 DOI: 10.1051/medsci/20153110010] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
Peripheral T-cell lymphomas (PTCL) belong to the group of non-Hodgkin lymphoma and particularly that of mature T/NK cells lymphoproliferative neoplasms. The 2008 WHO classification describes different PTCL entities with varying prevalence. With the exception of the histological subtype "ALK positive anaplastic large cell lymphoma", PTCL are characterized by a poor prognosis. The mechanisms underlying the pathogenesis of these lymphomas are not yet fully understood, but development of genomic high-throughput analysis techniques now allows to extensively identify the molecular abnormalities present in tumor cells. This review aims to summarize the current knowledge and recent advances about the molecular events occurring at the origin or during the natural history of main entities of PTCL. It will be published in two parts : the first is focused on the three more frequent entities, angioimmunoblastic T-cell lymphoma, peripheral T-cell lymphoma, not otherwise specified, and anaplastic large cell lymphoma. The second (which will appear in the november issue) will describe other subtypes less frequent and of poor prognosis : extranodal NK/T-cell lymphoma, nasal type, adult T-cell leukemia/lymphoma, and enteropathy-associated T-cell lymphoma. T or NK cell lymphoproliferative disorders with leukemic presentation, primary cutaneous T-cell lymphoma and very rare subtypes of PTCL whose prevalence is less than 5% (hepatosplenic T-cell lymphoma and subcutaneous panniculitis-like T cell lymphoma) will not be discussed herein.
Collapse
Affiliation(s)
- Lucile Couronné
- Service d'hématologie adultes, Assistance publique-hôpitaux de Paris (APHP), hôpital Necker, Paris, France - Inserm UMR1163, CNRS ERL 8254, Institut Imagine, Paris, France - Université Paris Descartes-Sorbonne Paris Cité, Paris, France
| | - Christian Bastard
- Service d'anatomo-pathologie, AP-HP, groupe hospitalier Henri Mondor-Albert Chenevier, Créteil, France; Université Paris-Est, faculté de médecine, Créteil, France ; Inserm U955, institut Mondor de recherche biomédicale, Créteil, France
| | - Philippe Gaulard
- Inserm, U918 ; Université de Rouen ; centre Henri Becquerel, Rouen, France
| | - Olivier Hermine
- Service d'hématologie adultes, Assistance publique-hôpitaux de Paris (APHP), hôpital Necker, Paris, France - Inserm UMR1163, CNRS ERL 8254, Institut Imagine, Paris, France - Université Paris Descartes-Sorbonne Paris Cité, Paris, France
| | - Olivier Bernard
- UMR 1170 ; Institut Gustave Roussy, 94805 Villejuif, France ; Université Paris Sud 11, Orsay, France
| |
Collapse
|
4
|
Zwiller J. [Epigenetics and drug addiction: a focus on MeCP2 and on histone acetylation]. Med Sci (Paris) 2015; 31:439-46. [PMID: 25958763 DOI: 10.1051/medsci/20153104019] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
Chronic drug exposure alters gene expression in the brain, which is believed to underlie compulsive drug seeking and drug taking behavior. Recent evidence shows that drug-induced long-term neuroadaptations in the brain are mediated in part by epigenetic mechanisms. By remodeling chromatin, this type of regulation contributes to drug-induced synaptic plasticity that translates into behavioral modifications. How drug-induced alterations in DNA methylation regulate gene expression is reviewed here, with a focus on MeCP2, a protein binding methylated DNA. The importance of histone modifications, especially acetylation is also discussed, with an emphasis on the effects of inhibitors of histone deacetylases on drug-induced behavioral changes. The precise identification of the epigenetic mechanisms that are under the control of drugs of abuse may help to uncover novel targets for the treatment of drug seeking and relapse.
Collapse
Affiliation(s)
- Jean Zwiller
- Laboratoire de neurosciences cognitives et adaptatives, UMR 7364, CNRS, université de Strasbourg, faculté de psychologie, 12 rue Goethe, 67000 Strasbourg, France
| |
Collapse
|